Scalable, automated, multi-end point health metrics

Our patented biophotonics platform analyses and captures multiple end-point data from living worms, providing rich integrated measures on the effect of your compound or product. In contrast to manual assays, that are well-established in academic research to measure health, ageing, toxicity (death) and disease in C. elegans, our WormGazer™ Technology confers several advantages:

• A robust workflow for high data reproducibility and rapid turnaround
• Non-invasive and continuous data acquisition
• Versatile data processing to reveal subtle and diverse health intervention effects
• Time-efficient and not subject to operator variation
• Multiple rich data points throughout all life stages
• Fully customisable healthspan approach (not just lifespan - live/dead)
• Solid agar media promotes free-moving native behaviour for reliable and representative data (unlike microchips) 

See our recent paper showing how WormGazer™ matches the data from a 40-day manual lifespan data in just 7 days

Robust and fast assay workflow with high data reproducibility and sensitivity

Over 80+ years of world-leading expertise in C. elegans research, combined with our WormGazer™ Technology ensures all aspects of our assays are conducted with the utmost consistency. Our automated approach is optimal for standardised data acquisition with a non-invasive approach. For example, there are no abrupt changes in lighting or temperature, or mechanical disruption to our worm cultures.


Unlike competitors, our technology enables us to maintain worms in a more natural, free-moving environment (as opposed to microchips), to encourage native behaviour and reliable data outcomes. In addition, WormGazer™ Technology allows continuous data acquisition with multiple culture plates per test conditions. Tracking images are taken every 0.8 sec for 160 secs, every 5 minutes, 24 hours a day with an extensive duration (up to 14 days).


As a result, we can generate a petabyte of relevant data per week. This allows us to reliably detect small changes between test conditions to provide information about whether your product has a tight efficacy window and understand the complexity of dose responses. This rich data is customisable for a multi-faceted healthspan approach, enabling you to select diverse and highly relevant endpoints for your research — not just single data point outcomes.